Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $598.00 at Bank of America

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price lifted by Bank of America from $571.00 to $598.00 in a research note published on Tuesday morning,Benzinga reports. Bank of America currently has a buy rating on the pharmaceutical company’s stock.

VRTX has been the subject of several other research reports. Stifel Nicolaus lifted their target price on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a report on Friday, February 13th. Leerink Partners upped their price target on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, December 29th. Citigroup raised their price target on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright boosted their price objective on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Canaccord Genuity Group increased their target price on Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research note on Tuesday, February 17th. Twenty-three research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $551.77.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $499.17 on Tuesday. The stock has a market capitalization of $126.80 billion, a P/E ratio of 32.56 and a beta of 0.31. The firm’s 50-day moving average is $468.41 and its two-hundred day moving average is $436.53. Vertex Pharmaceuticals has a 12 month low of $362.50 and a 12 month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same quarter in the prior year, the business earned $3.98 earnings per share. Vertex Pharmaceuticals’s revenue was up 9.5% on a year-over-year basis. As a group, analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Mark E. Bunnage sold 2,021 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $930,529.03. Following the sale, the executive vice president owned 12,914 shares of the company’s stock, valued at approximately $5,945,993.02. This represents a 13.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Duncan Mckechnie sold 4,910 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the sale, the executive vice president owned 17,559 shares in the company, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 91,156 shares of company stock valued at $42,845,497. Corporate insiders own 0.20% of the company’s stock.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Chesapeake Asset Management LLC grew its position in shares of Vertex Pharmaceuticals by 110.0% during the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 33 shares in the last quarter. Motiv8 Investments LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $26,000. Colonial Trust Co SC lifted its stake in Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 38 shares during the last quarter. Swiss RE Ltd. purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $28,000. Finally, Eagle Bay Advisors LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported positive Week‑36 interim results from the Phase 3 RAINIER trial for povetacicept — the study met its primary and all secondary endpoints, supporting the drug’s potential as a best‑in‑class treatment for IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: News outlets note the trial win as a major validation — coverage emphasizes the result as a “key test” passed and calls the data “remarkable,” boosting confidence in Vertex’s kidney‑disease strategy. Vertex passes key test In quest to treat kidney diseases
• Positive Sentiment: Interim efficacy metrics cited in coverage (e.g., ~52% reduction in proteinuria) raise hopes for meaningful clinical benefit and potential for an accelerated FDA filing pathway, increasing the drug’s peak‑sales and valuation assumptions. VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
• Positive Sentiment: Multiple brokerages responded quickly with higher price targets and fresh buy/outperform ratings (examples: Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citi, Jefferies, BMO and others), reflecting analysts modeling substantial upside from povetacicept. Benzinga — analyst price target coverage
• Neutral Sentiment: Vertex presented at the Leerink Global Healthcare Conference (transcript available), which may provide additional detail on timing, filing plans and commercial strategy but is less market‑moving than the trial headlines. Vertex Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and aggregator pieces (Barron’s, Yahoo, Investopedia, TipRanks) are amplifying the newsflow — helpful for liquidity and momentum but reflecting the same core trial announcement rather than new independent data. Investopedia — trial results coverage

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.